Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757695 | 0.92 | PTGDR2 (0.45) | PTGDR2DGAT2KDM4EALDH1A1JAK2 | |
| SCHEMBL1757983 | 0.91 | PTGDR2 (0.45) | PTGDR2DGAT2KDM4EALDH1A1JAK2 | |
| SCHEMBL1757753 | 0.85 | PTGDR2 (0.51) | PTGDR2ALDH1A1PTGDR | |
| SCHEMBL1757714 | 0.83 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL1757993 | 0.81 | PTGDR2 (0.46) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL1757478 | 0.81 | PTGDR2 (0.46) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL1757736 | 0.74 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL1757156 | 0.74 | PTGDR2 (0.45) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL2206918 | 0.74 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL1758074 | 0.74 | PTGDR2 (0.48) | PTGDR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885DGAT2 2950/4885KDM4E 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.